Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value

We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Corbus Pharmaceuticals Holdings, Inc. is among the best biotech stocks.

TheFly reported on April 7 that Mizuho raised its price target on CRBP from $39 to $40 while maintaining an Outperform rating. The firm updated its valuation model following the company’s fourth quarter results. The corporation is expected to deliver three clinical data readouts during 2026, which the firm views as key upcoming catalysts. Mizuho also noted that the stock is currently trading near the company’s cash position, suggesting limited downside and an attractive risk-reward profile ahead of multiple potential data-driven events.

Additionally, on April 7, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced it has reached broad alignment with the U.S. FDA on the registration strategy for CRB-701, a next-generation Nectin-4 targeting antibody-drug conjugate being developed for head and neck squamous cell carcinoma and cervical cancer.

Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value

The planned registrational approach includes separate randomized controlled studies in each indication comparing CRB-701 to standard chemotherapy regimens, with objective response rate as the basis for potential accelerated approval and overall survival as the confirmatory endpoint for full approval. The company will continue discussions with the FDA to finalize study protocols and statistical analysis plans. In addition, Corbus disclosed a leadership change, with its chief medical officer stepping down effective June 30, 2026.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies for inflammatory and fibrotic diseases. It is also expanding into oncology, aiming to create targeted treatments that modulate the immune system and improve patient outcomes.

While we acknowledge the risk and potential of CRBP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CRBP and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest in According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.